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Lower respiratory symptoms with wheeze are common in early childhood (1). Most young children 3 
cease to wheeze before school age (2), but some early childhood risk factors may determine the 4 
lifelong respiratory outcome. Clinical characteristic  associated with persistent wheeze include 5 
maternal smoking, parental asthma, severity of wheezing, atopy and elevated IgE (3,4). Increased 6 
airway hyperresponsiveness (AHR) in infancy has also been connected to persistent symptoms later 7 
in life (5-7).  8 
The role of AHR in the pathogenesis of respiratory symptoms in young children is incompletely 9 
understood. Most reports have evaluated AHR in birth cohorts, and only one investigation focused 10 
on symptomatic infants (7). Some studies have provided evidence that AHR is present in all young 11 
children, at least those under one year of age, independently of the presence of respiratory 12 
symptoms (8-10). Contradictory results have also been r ported. Increased AHR at the age of one 13 
month in children with atopic mothers was associated with asthma by the age of 7 years (5). 14 
Another study reported an association between increased AHR in neonates and decreased lung 15 
function, asthma and respiratory tract symptoms at 6 years of age (6). When AHR was assessed in 16 
children with wheeze before 2 years of age, a significantly higher reactivity to methacholine was 17 
found in children with persistent wheeze than in symptom-free children, but the level of AHR was 18 
not predictive of asthma 4 years later (7).  19 
We aimed to determine whether AHR in symptomatic infants (6 to 24 months) could predict doctor-20 
diagnosed asthma (DDA), defined as the need for regular control medication at the median age of 6 21 
years. Secondary aims were to clarify whether AHR assessed in infancy persists and to identify 22 
other predisposing factors associated with persistence of lower respiratory symptoms at the median 23 


















Patients  27 
Children born full term and aged 6-24 months, referr d for lung function measurements, originally 28 
participating in a study evaluating the efficacy of montelukast (11), were recruited between 29 
September 2004 and April 2008. Study was prospectiv w th observational design. Inclusion criteria 30 
included a history of persistent troublesome lower respiratory tract symptoms (wheeze, cough, 31 
dyspnea), at least one physician-diagnosed wheezing pisode and successfully performed 32 
methacholine challenge test.  Exclusion criteria were: a need for inhaled corticosteroids (ICS) 33 
within 8 weeks prior to the first visit; a cumulative life-time systemic prednisolone use for more 34 
than 3 days at a dose of  2 mg/kg, or an equipotent dose of another systemic corticosteroid or life-35 
time ICS use more than 4 weeks; respiratory infection in the 14 days preceding the lung function 36 
measurement, or any obvious structural defect.  37 
Out of of 367 enrolled, 254 were not randomized because 1. did not fulfil the criteria (n=224), 2. 38 
technical problems (n=11), 3. sedation problems (n=9), 4. not willing to participate (n=10)(11). 39 
After original study enrollment three more children performed the lung function measurements, 40 
fulfilled the inclusion criteria and are included in the present study. A total of 61 out of 116 children 41 
from the original study were able to participate in this follow-up study and performed all of the lung 42 
function measurements at median age of 6 years. 43 
 44 
Lung function measurements 45 
















The measurements of lung function were performed by using commercial equipment (Body 47 
Masterscreen; Jaeger GmbH, Wurtzburg, Germany) as described previously (12). Infant whole-48 
body plethysmograph was applied to measure functional residual capacity (FRC) and specific 49 
airway conductance (sGaw) (12-14). The maximal flow at functional residual capacity (V’maxFRC) 50 
was determined using the squeeze technique as reported elsewhere (12,15). Fractional concentration 51 
of exhaled nitric oxide (FeNO) was measured with a modification of the online single-breath 52 
technique (16,17). The methacholine challenge test wa  performed with a dosimetric protocol as 53 
described previously (12). The provocative dose of methacholine to cause a 40% decline in 54 
VmaxFRC (PD40VmaxFRC) was determined. A PD40VmaxFRC lower than 300 µg was 55 
considered a positive test result (12). 56 
 57 
Follow-up evaluation 58 
Lung function tests were performed using impulse oscill metry (IOS). Regular asthma control 59 
medication was stopped at least 4 weeks before the lung function measurements. Respiratory 60 
system resistance at 5 Hz (Rrs5) and 20 Hz (Rrs20) as well as reactance at 5 Hz (Xrs5) were 61 
determined by IOS as described previously (18-20). AHR was determined by exercise challenge 62 
and methacholine challenge tests as described elsewher  (21).  63 
Briefly, the exercise challenge test was performed as a standardized outdoor running test (18) 64 
lasting for 6 to 8 minutes at 85 % to 90 % of maximal heart rate. IOS was performed before and at 65 
1, 5 and 10 minutes after exercise. A post-exercise increase of 35% in Rrs5 was considered a 66 
positive test result (18).  67 
Methacholine challenge test was applied by a dosimetric bronchial provocation test modified to be 68 
appropriate for preschool children (12,21). First, the baseline Rrs5 was determined, and thereafter, 69 
















dosimeter (Spira Electro 2, Spira Respiratory Care Centre, Ltd., Hämeenlinna, Finland) connected 71 
to a calibrated nebulizer (Salter Labs 8900, Arvin, CA, USA). Rrs5 was measured 90 seconds after 72 
each methacholine inhalation. The procedure was continued until a 40% increase in Rrs5 was 73 
observed or the maximum dose of methacholine was administered. The provocative dose of 74 
methacholine causing a 40% increase in Rrs5 (PD40Rrs5) was determined from the dose-response 75 
curves (22,23). A PD40Rrs5 lower than 400 µg was considered a positive test result (24).  76 
At both study points, the dose-response slope (DRS) was calculated by dividing the percentage 77 
change in the observed lung function parameter (Rrs5 o  VmaxFRC) by the cumulative dose of 78 
methacholine at the last inhalation. This value was then log transformed to normalize the 79 
distribution (LOGDRS). The methacholine test results were analyzed both as categorical data 80 
(positive/negative) and as continuous data (PD40VmaxFRC, PD40Rrs5 and LOGDRS).  81 
FeNO was measured with a stationary chemiluminescence-based device (NIOX, Aerocrine AB, 82 
Solna, Sweden) according to the American Thoracic Society recommendations (16).  83 
 84 
Atopic status 85 
Atopic status was defined as positive skin prick test reactivity to birch, timothy grass, meadow 86 
fescue, mugwort, Cladosporium herbarum, cat, dog, hrse, cow, house dust mite, milk, egg, fish, 87 
wheat, shrimp and peanut. Positivity in skin prick tests was defined as a wheal of at least 3 mm 88 
diameter in reaction to at least one of the tested all rgens. Blood samples at infancy were examined 89 
to assess eosinophil count and IgE level by the routine laboratory methods used in Helsinki 90 
University Central Hospital (25). Also children with doctor-diagnosed atopic eczema were 91 


















Other characteristics of the study children 95 
Individual and family histories of both respiratory and allergy symptoms, diagnoses, asthma 96 
medication, allergies and smoking status were assessed by a questionnaire at both stages of the 97 
study.  98 
 99 
Asthma predictive index (API) 100 
API was defined at the follow-up visit and was considered positive if a child fulfilled at least one 101 
major criterion or two minor criteria. Major criteria include parental asthma, doctor-diagnosed 102 
atopic dermatitis and sensitization to aeroallergen. Minor criteria include allergic sensitization to 103 
food, blood eosinophils ≥ 4% and wheezing unrelated to colds (26, 27). 104 
 105 
Doctor-diagnosed asthma (DDA) 106 
Doctor-diagnosed asthma was defined as need for regular asthma control medication at the follow-107 
up assessment (median age of 6 years) (28). 108 
 109 
Statistical methods 110 
Normal distribution was tested with Shapiro-Wilks test. Because values were not normally 111 
distributed, non-parametric tests were used. Categorical data were analysed with Chi-square test and 112 
continuous data with Mann-Whitney U-test. Bivariate correlation was calculated by the Spearman 113 
correlation test. Effect size for Spearman coefficient (rho) is considered small if rho is ≤ 0.29, 114 
















logistic regression, where DDA was a dependent variable and gender, FeNO, number of wheezing 116 
episodes and infant methacholine PD40VmaxFRC were covariates. Data were analysed using SPSS 117 
19.0 (SPSS, Inc, Chicago, IL, USA). 118 
 119 
Ethics 120 
The study was approved by the Ethics Committee of Helsinki University Central Hospital 121 





















Tables 1 and 2 represent baseline characteristics of 61 children at infancy and at follow-up, 128 
respectively. No significant differences in patient characteristics were found between children who 129 
participated in the follow-up study and those lost to follow-up (Table 1). The median interval 130 
between the two stages of the study was 4.6 years (range 3.6-7.3 years).  131 
 132 
AHR in infancy and associations with AHR and DDA at 6 years 133 
In infancy (at age 6 to 24 months), all study children had recurrent lower airway symptoms 134 
including periodic wheezing and regular asthma control medication. Symptoms in infancy are listed 135 
in Table 1.  At a median age of 6 years, 21 (34%) of the 61 children had doctor-diagnosed asthma 136 
(DDA). Children with DDA at 6 years had lower PD40VmaxFRC to methacholine, indicating 137 
increased AHR in infancy relative to children without DDA (p = 0.022, Table 3). In addition, infant 138 
methacholine LOGDRS was higher in children who had DDA at 6 years than in children without 139 
DDA (0.047 vs. 0.025, p=0.033, Figure 1). Children with DDA at 6 years had also increased current 140 
AHR to methacholine compared with children without DDA (p = 0.029).  141 
 142 
Methacholine LOGDRS at infancy and at 6 years of age were significantly associated with each 143 
other (p = 0.011, rho 0.324, Figure 2). Furthermore, children with positive methacholine challenge 144 
at 6 years had higher median infant LOGDRS than children with negative methacholine challenge 145 
at 6 years (0.031 vs. 0.025, p = 0.047, Figure 1). Exercise-induced bronchoconstriction (EIB) was 146 
present in 8 children (13%) at 6 years. Children with EIB had higher methacholine LOGDRS in 147 

















API and AHR  150 
In all, 49 children (80%) had positive API at follow-up. No associations between positive API and 151 
methacholine LOGDRS (p = 0.842) or methacholine positivity (p = 0.877) at age of 6 were found. 152 
In addition, no associations between API status and FeNO level or EIB at age 6 years existed. 153 
Methacholine LOGDRS in infancy did not differ significantly between API-positive and API-154 
negative children (p = 0.301).  API status was not associated with DDA at 6 years (p = 0.443), but 155 
API-positive children had more symptoms at 6 years than API-negative children (75 % vs. 0%, p = 156 
0.005). 157 
 158 
AHR and lung function 159 
Lung function (sGaw or VmaxFRC) at infancy was not associated with DDA or lung function at 160 
age 6 years. No association between infant AHR and lu g function at 6 years was found. 161 
 162 
FeNO measurements 163 
Only a weak trend was observed between FeNO levels in infancy and early childhood (r = 0.558; p 164 
= 0.078). FeNO level in infancy was not associated with DDA or AHR at age of 6. Children with 165 
atopic status in infancy (SPT positivity and/or atopic eczema) had higher FeNO levels at age 6 years 166 



















Infant atopic markers in association with preschool symptoms 171 
Children with EIB had more often positive skin prick test result (p = 0.002) and higher IgE level (p 172 
= 0.025) in infancy than children without EIB, but these markers were not associated with DDA at 173 
the age of 6 years.  174 
 175 
Multiple regression analysis 176 
In multivariate logistic regression analysis, a higher PD40VmaxFRC to methacholine in infancy 177 
was associated with a lower risk for DDA at 6 years of age (OR 0.185, CI 0.04 – 0.926, p 0.040, 178 
Table 4). Gender, number of wheezing episodes and FeNO level in infancy were not associated 179 




















We followed airway hyperresponsiveness in children with recurrent respiratory symptoms before 2 185 
years of age from infancy until the age of 6 years. We showed that higher methacholine LOGDRS 186 
indicating increased AHR in symptomatic infants was associated with doctor-diagnosed asthma 187 
(DDA) and exercise-induced bronchoconstriction (EIB) at the age of 6 years. Furthermore, 188 
hyperresponsiveness to methaholine in infancy and at 6 years were associated with each other, 189 
suggesting persistence of AHR over early childhood.  190 
All of our study children had recurrent lower respiratory tract symptoms, including wheezing, 191 
before the age of 2 years and were using regular asthm  control medication. At the later study point 192 
(median age 6 years), 34% of these children were using regular asthma medication (defined as 193 
DDA). This is in line with the findings of several cohort studies (3,29) as well as with Delacourt et 194 
al. (7,30), who showed persistent wheezing at 5 years in 38 % of children with infantile asthma. 195 
Earlier studies have also suggested that higher frequency of symptoms in infancy and persistent 196 
wheezing phenotype during the preschool years is connected to more severe asthma in later 197 
childhood (30).  198 
Asthma predictive models, such as API, have been developed to aid asthma diagnostics at an early 199 
age (26). However, the usefulness of API to predict future asthma is only modest since its positive 200 
predictive value (PPV) for asthma at age 7 years is only reported to be 26% (31). Here, API-201 
positive children experienced more symptoms than API-negative children at age 6 years, but there 202 
was no connection to DDA or AHR. Our study population is, however, small and the children 203 
represent a highly selected group with early asthmaic symptoms. This may have obscured the 204 
impact of API criteria. 205 
Infant lung function and its predictive value for later asthma symptoms have been examined in 206 
















those without DDA at 6 years. In a Tucson cohort, children with transient wheeze had decreased 208 
VmaxFRC in infancy before the symptoms appeared, but infant VmaxFRC was not able to 209 
differentiate persistent wheezers from non-wheezers (3). Delacourt et al. (7) showed a lower 210 
VmaxFRC in infants with persistent wheeze at the agof 5 years than in children who stopped 211 
wheezing. Although diminished lung function at infacy has been linked to later symptoms, it is 212 
diffucult to define cut-off levels and significant overlap in phenotypes exists regarding disease 213 
progression. (7) In the present study, no significant differences in IOS lung function parameters 214 
between children with DDA at 6 years and children with no DDA emerged. Some earlier studies 215 
have shown diminished lung function in persistent wheezers compared with never-wheezers or 216 
those who stopped wheezing (3,4,30).  217 
Our study revealed an association between AHR to methacholine at infancy and DDA but not lung 218 
function at age 6 years. Most of the knowledge on the connection between infant AHR and 219 
persistence of symptoms and later lung function derives from cohort studies.  As far as we are 220 
aware, there is only one earlier study examining persistence of AHR and connection of AHR and 221 
later symptoms in symptomatic young children (7). Delacourt et al. (7) reported altered lung 222 
function at the age of 5 years in children with AHR and asthma at 16 months. Clarke et al. (32) 223 
determined lung function and AHR with histamine in 73 healthy neonates. AHR was increased in 224 
those female neonates who subsequently experienced wh ezy episodes during the first year of life. 225 
In an Australian birth cohort 243 children (6,33), an association was found between increased infant 226 
AHR and decreased lung function and lower respiratory symptoms at the age of 6 years (6), but no 227 
longer at 11 years (33).  228 
We found persistency of infant AHR at six years in symptomatic children, in accord with findings 229 
elsewhere (30). Both increased neonatal AHR and diminished lung function among high-risk 230 
Danish neonates were connected to development of ashm  by age 7 years (5). Our study evaluated 231 
















challenge test was performed at the later stage, i.e. at 6 years. The use of these direct and indirect 233 
AHR tests at 6 years enabled us to evaluate different mechanisms of AHR (34). Although a precise 234 
and clear definition for early childhood asthma is lacking, AHR shown in indirect tests such as an 235 
exercise challenge test, is thought to be more specific for paediatric asthma (35). We showed that 236 
EIB at age 6 years was associated with higher reactivity to methacholine in infancy, suggesting that 237 
even indirect AHR may be affected by susceptibility already present in infancy. Children with EIB 238 
had more symptoms during the last 12 months than children with no EIB, but the symptoms were 239 
not associated with infant AHR. AHR at different time points in life may manifest via various 240 
pathophysiological mechanisms, and according to the present findings, AHR in early life may be a 241 
predictor for later asthmatic symptoms. Our study suggests that children with multiple wheeze 242 
episodes and increased AHR to methacholine before 2 y ars of age may have permanent airway 243 
dysfunction with susceptibility to airway narrowing, possibly arising from structural changes with 244 
either increased airway muscle force or mechanical load of the airway (36). The study design and 245 
sample does not allow us to make conclusions about specific clinically meaningful levels of AHR 246 
that would indicate later asthma. 247 
One of the shortcomings in this study is the selectd patient population with lower respiratory tract 248 
symptoms and the lack of controls. However, this setting reflects the situation in day-to-day 249 
preschool asthma prognosis assessment. In addition, the sample size is relatively small and many 250 
children did not participate the follow-up, which is a common feature in these studies. To control 251 
for this effect, we analysed the demographics of participating and non-participating children and 252 
found no significant differences between the groups.  253 
Interpretation of AHR test results in young children is ambiguous. We applied cut-off limits of 254 
AHR, which we have previously shown to be associated with current symptoms in infants (17), but 255 
there is no unequivocal cut-off level for the methacholine challenge test in predicting later asthma 256 
















A provocative dose cut-off level of 400 µg in methacholine challenge in preschool children has258 
been suggested to be associated with probable asthm (21,24). 259 
In conclusion, AHR in infancy and AHR at 6 years of age were associated in children with recurrent 260 
wheezy symptoms in infancy. In addition, increased AHR in infancy was connected to DDA and 261 
EIB in early childhood. This suggests an early development of increased airway responsiveness in 262 
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Figure 1.  
Comparison of infant methacholine LOGDRS in children at 6 years a) with and without 
asthma b) with negative or positive methacholine test and c) with negative or positive exercise 
test  
 


















Table 1. Characteristics at infancy 
 






Age, months, median (range) 15.1 (6-24) 15.0 (6-24) 0.761 
Male, n (%) 50 (82) 36 (66) 0.056 
Parental smoking, n (%) 21 (34) 16 (29) 0.557 
Maternal smoking, n (%) 14 (23) 13 (24) 0.930 
Parental asthma, n (%) 28 (46) 21 (38) 0.454 
Skin prick test positivity*, n (%) 17 (28) 15 (27) 0.899 
All episodes, mean ( range) 2.4 (1-6) 2.7 (1-7) 0.456 
Wheezing episodes, mean (range) 2.2 (1-4) 2.2 (1-3) 0.635 
Hospital admission, mean (range) 0.3 (0-2) 0.3 (0-1) 0.785 
Atopic eczema, n (%) 21 (34) 25 (46) 0.708 
Duration of symptoms, months, median 
(range) 
8.5 (2-19) 7.4 (2-21) 0.364 
VmaxFRC, z-score, median (range) -1.3 (-3.8-1.2) -1.0 (-3.5-1.2) 0.179 
FeNO, ppb, median (range) 18 (0-134) 22.4 (0-59) 0.132 
IgE, ku/l, median (range) 17.5 (1-2061) 17 (0-685) 0.258 
PD40VmaxFRC, µg, median (range) 570 (50 - 3600) 480 (50-3600) 0.918 
 

















Table 2. Characteristics at median age of 6 (n=61) 
 
 
Age (y), median (range) 6.0 (5.6 - 8.1) 
Male, n (%) 50 (82) 
Parental smoking, n (%) 18 (30) 
Maternal smoking, n (%) 10 (16) 
Parental asthma, n (%) 28 (46) 
Skin prick test positivity, n (%) 19 (31) 
Current medication, n (%) 21 (34) 
Seasonal medication, n (%) 10 (16) 
Symptoms* during previous 12 
months, n (%) 
21 (34) 
 
Wheezing during previous 12 
months, n (%) 
8 (13) 
Rrs5 z-score, median (range) 0.33 (-1.78-3.53) 
MPT positivity, n (%) 48 (79) 
PD40V’maxFRC, µg, median 
(range) 
190 (20-2060) 
LOGDRS, median (range) 0.08 (0-0.52) 
FeNO, z-score, median (range) 1.2 (-1.2-3.8) 
Eosinophils 0.28 (0.04-1.38) 
 
 
*wheezing, cough, symptoms during exercise 
MPT = methacholine provocation test 















Table 3. Lung function, AHR, FeNO, atopic markers and infant symptoms 
according to doctor-diagnosed (DDA) asthma at age of 6 years.  
 
 DDA (n=21) No DDA (n=40) p 
FRC, z-score, 
median (range) 
1.2 (-1.8-4.8) 0.6 (-2.8-4.8) 0.374 
sGaw, z-score, 
median (range) 




-1.4 (-3.1-1.0) -1.1 (-3.8-1.2) 0.485 
Infant 
PD40V’maxFRC, 
µg, median, range 
330 (50-3600) 620 (50-3600) 0.083 
MPT positivity at 
infancy, n (%) 
20 (95) 28 (70) 0.022 
Infant LOGDRS, 
median (range) 
0.047 (0.01-0.19) 0.025 (0-0.21) 0.033 
Infant FeNO 19 (2-56) 18 (0-134) 0.730 
Infant eosinophils, 
median (range) 
0.35 (0.1-0.9) 0.26 (0.01-1.16) 0.242 
Infant IgE, median 
(range) 
22 (11-452) 16 (1-2061) 0.053 
Infant skin prick 
test positivity, n (%) 
7 (33) 10 (25) 0.418 
Episodes in infancy 2 (1-4) 2 (1-6) 0.057 
Hospital admission 
in infancy 
0 (0-1) 0 (0-2) 0.860 
Rrs5, z-score, 
median (range) 
0.52 (-1.78-3.53) 0.26 (-1.7-2.3) 0.366 
Postexercise Rrs5 
increase (%) 
21 (-16-111) 18 (-12-83) 0.342 
MPT positivity at 
age 6, n (%),  
19 (90) 29 (73) 0.103 
PD40Rrs5 at 6 
years, µg, median 
(range) 
150 (20-810) 230 (30-2060) 0.029 
LOGDRS at age 6, 
median (range) 
0.089 (0.01-0.52) 0.048 (0-0.37) 0.025 
FeNO at 6 years, z-
score, median 
(range) 
1.4 (-1.2-3.7) 1.0 (-0.8-3.8) 0.304 
 
 















Table 4. Odds ratio from the multiple regression analysis in which the outcome 
parameter was DDA at the age of 6 years. 
 
 OR (95 % CI) P value 
Number of wheezing 
episodes at infancy 
0.819 (0.38 - 1.76) 0.608 
Sex 2.946 (0.52 – 16.72) 0.223 
PD40VmaxFRC to 
methacholine at infancy 
0.185 (0.04 – 0.926) 0.040 
FeNO at infancy 1.0 (0.97 – 1.0) 0.964 
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